FATE   $3.13  -0.63% Market Open

Fate Therapeutics Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-08-05 Trend pattern changed from расширяющаяся формация to нисходящий клин.

2023-08-04 Trend pattern changed from расходящийся треугольник to расширяющаяся формация.

2023-08-04 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-03 Trend pattern changed from канал to расходящийся треугольник.

2023-08-02 Trend pattern changed from расширяющаяся формация to канал.


Current temperature: 6.57
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 13
Target Price Mean 6.58
Mean unverified/preliminary 6.58 / 6.58
Target Price Low / High 3.50 / 12.00
Median / STD DEV 5.00 / 2.58
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy None Sell
rsi Sell Sell Sell
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 Sell Buy Sell
ma50 None None None
ma100 ActivelyBuy Buy None
Candlestick PatternOct. 18, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US31189P1021
ceo Mr. J. Scott Wolchko
Website https://www.fatetherapeutics.com
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.